Effective management of SMARCA4-deficient undifferentiated tumor by immunotherapy combined with chemotherapy and radiotherapy: Case report
Our case of SMARCA4-UT exhibiting a high tumor mutational burden demonstrated a favorable response to the immunotherapy (tislelizumab) combined with chemotherapy and radiotherapy. This approach may represent a novel therapeutic strategy for SMARCA4-UT population.
Authors
- Tao Zheng (ORCID: https://orcid.org/0000-0003-0035-7109)
- Rong Huang (ORCID: https://orcid.org/0000-0003-4700-4466)
- Qingyu Ge
- Xin Liang (ORCID: https://orcid.org/0009-0009-5125-4821)
Institutions
- First People's Hospital of Chongqing (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1097/md.0000000000045747
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00